As previously reported, Wedbush initiated coverage of Abivax (ABVX) with an Underperform rating and $110 price target The firm notes Abivax is a clinical-stage biopharmaceutical company developing treatments for inflammatory and immune-mediated diseases. Wedbush urges caution on speculation around M&A rumors, and recommends investors either wait for Q2 data or take profits at current levels, given substantial downside risk if a deal should fail to materialized after the Q2 readout.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Abivax initiated with a Neutral at Wedbush
- Abivax Unveils Anti-Fibrotic and Phase 3 Safety Data for Obefazimod in IBD at ECCO 2026
- Magnifique! U.S. Chess Champion’s Healthiest 2026 Move – French Biotech Abivax (ABVX)
- Obefazimod: Favorable Risk‑Reward on Strong UC Efficacy, Emerging Crohn’s Opportunity, and Undervalued Commercial Upside
- Abivax presents preclinical data for obefazimod